Patent Application
20100028395
Differently to as it may seem, skin has a rather complex structure and may be schematically likened to the overlapping of three tissue layers, namely the epidermis, dermis and cutaneous tissue, each characterised by precise, well-differentiated functions.
The upper layer, known as epidermis, is somewhat resistant and appears thin under the microscope. It progressively wears out and is constantly renewed. It is translucent and allows light to only partially pass through, rather like ground glass. The epidermis doesn't contain any blood vessels, it receives oxygen and nutrients from the deeper layers of the cutaneous tissue, impedes excessive loss of moisture from the body and gives healthy skin an attractive look.
All the cells of the epidermis originate from a single layer known as the basal layer. The dominant cell type in the epidermis is the keratinocyte, which takes its name from its ability to synthesize keratin. Keratins are non-water soluble natural proteins with high resistance to temperature and pH; they are divided into hard and soft keratins: the hard keratins from the hair, skin and nails, while the soft keratins are the main components of the cornified cells of the outermost layers of the epidermis, and are also found, as connecting substances, in the extracellular space of other layers of the epidermis.
Besides the keratinocytes, the epidermis also contains melanocytes, which are localised in the basal layer and produce the skin pigment known as melanin, which, depending on the amount, determines the colour of skin and hair; furthermore, melanocytes increase the expression of melanin as a result of the effect of solar radiation as a defense reaction against potential damage caused by the impact of ultraviolet rays on skin tissue.
The already-mentioned basal layer, separating the dermis from the epidermis, consists precisely of melanocytic cells and cylindrical keratinocytes, in charge of cellular mitosis, guaranteeing the continuous epidermal regeneration, and the cellular division of which depends, in turn, on the role played by other substances such as the various growth factors, hormones and assorted vitamins.
Between the basal layer of the epidermis and the dermis is located the basal membrane (itself also devoid of blood vessels), also known as the dermo-hypodermic junction which, besides separating the two cutaneous layers, is also involved in anchoring basal cells to the dermis and mediating various nutritional and metabolic functions.
The second layer, i.e. the dermis, contains blood vessels, nerves, the hair roots, sweat glands and all the structures conferring strength and elasticity to the skin.
The dermis is mainly composed of horizontal collagen bundles running across it and immersed in gelatinous substance known as fundamental substance, which in turn forms part of the extracellular matrix. Collagen constitutes up to 75% of the weight of the dermis and is responsible for the tonicity and elasticity of the skin. The collagen bundles are held together by elastic fibres made of a protein called elastin, which represents less than 5% of the weight of the dermis and, despite the name, is not directly responsible for the natural elasticity of skin.
Both the collagen and the elastic fibres are produced by cells known as fibroblasts, which are found in the dermis. Fibroblasts not only produce and organise the extracellular matrix of the dermis, but also communicate between one another and with other cell types, performing very important functions in the physiology of the skin such as, for example, the release of growth factors/cytokines which, in turn, play a significant role in wound healing by modulating keratinocyte activity (Sorrell M. and Caplan AI 2004).
Hyaluronic acid (HA) is another fundamental component of elastoviscous extracellular matrix in which the collagen fibres, elastic fibres and other cellular structures are immersed. It has the capacity to attract water in quantities equal to hundreds of times its weight, and thus represents a natural hydrating substance, responsible for the tonicity of the skin and its reserves of moisture. Furthermore, HA facilitates the transport of essential nutrients from the blood to skin cells. HA is a natural, linear polysaccharide composed of a disaccharide structural unit constituted by D-glucuronic acid and N-acetyl-glucosamine (NA) monosaccharides, and is present in all living organisms. Unlike collagen, hyaluronic acid shows no tissue or species specificity and is neither allergenic or irritant.
Another class of substances present in extracellular matrix, and closely structurally and functionally associated with HA, is represented by the glucosaminoglycans (GAGs). These are constituted by long chains of disaccharidic units wherein the monomers are represented by glucosamine or galactosamine and uronic acids. GAGs carry negative charges, due to the presence of sulphonic groups and the aforementioned uronic acids (and this structure explains their powerful capacity to attract negative ions and enormous quantities of H2O), and become attached to protein chains (core proteins) to form the proteoglycans. Proteoglycans are the major component of extracellular matrix and, together with HA, to which they are covalently bound (by means of link proteins), and collagen fibres, constitute the extracellular structure of connective tissue, and hence skin, conferring said tissue with the majority of its characterising mechanical/functional characteristics.
Finally, the innermost part of the skin is represented by the hypodermis or subcutaneous layer, consisting of blood vessels, nerves and adipocyte clusters. From the structural viewpoint, the separation from the overlying dermis is not well defined, while deeper, the hypodermis is bound to the underlying muscle and adipose tissue, which is deposited therein in varying amounts, and exerts a well defined isolating and modelling function.
Various studies have been conducted with the scope of determining the effect of hyaluronic acid and other substances on skin cell activity.
With advancing age, skin elasticity and tone reduces visibly with the consequent appearance of wrinkles of various depths and loss of the turgor characteristic of younger more aesthetically pleasing skin. This ageing is essentially associated with slowed turnover of both HA, with consequently reduced capacity to absorb/retain tissue moisture, and collagen, with deterioration of the other functional characteristics of skin, such as resistance to external stress and elasticity.
The search for substances to be used in dermo-cosmetology and aesthetic medicine for topical use or as a skin filler for the correction of facial skin wrinkles and for enhancement of soft facial tissue, has been subject to continual effort for a number of years. Various biomaterials are currently available, but all have shown burdensome limitations: they are either absorbed too quickly and are thus of no practical use, or they can give rise to allergic reactions (such as for example in the case of collagen), or even migrate away from the site of injection.
A safe and effective substance for the above-mentioned uses must be biocompatible, non-pyrogenic, must be neither allergenic nor toxic, must not cause inflammation, must be easy to use, stable and not migrate following injection, must last for as long as possible but at the same time, must be reabsorbable and must give the skin a natural look: due to its physico-chemical and mechanical/structural characteristics, hyaluronic acid has shown itself to be able to simultaneously satisfy all these functional requirements. It was developed as a skin filler for the first time in 1989 by E. Balazs, who observed the biocompatibility and absence of immunogenicity (Balazs E. A. and Leshchiner E. A. 1989).
Exogenous hyaluronic acid is quickly reabsorbed by the dermis and metabolised in the liver with the formation of carbon dioxide and water. The HA reabsorption process is rapid and complete, and depends on receptor binding and intracellular degradation. The half-life in the skin is very short, i.e. less than 24 hours.
In order to obviate said drawback, hyaluronic acid for use as a prolonged effect filler may be chemically cross-linked. While keeping unaltered its biocompatibility, the cross-linking process alters the solubility and rheological properties of this polysaccharide, becoming more viscous and assuming the consistency of a gel. Hyaluronic acid gels used as skin fillers are “hydrogels”, since they are reswollen by 95% of their weight in water and remain stable in tissue, being reabsorbed only after several months, thus making them advantageous for use in dermo-cosmetology and aesthetic medicine.
A further advantage is represented by the fact that, unlike other temporary fillers such as collagen, hyaluronic acid-based gels are eliminated from the tissue by isovolumic degradation and that, little by little, as the molecules of hyaluronic acid are degraded and eliminated, the residues can bind more water, with the advantage that the entire volume injected remains unchanged.
To complete the picture on the use of hyaluronic acid in dermo-cosmetology, it should be underlined that, in its non-cross-linked form, it may be advantageously used both as it is, and in association with other active ingredients, in solutions, gels, creams or other forms for topical application, with obvious beneficial effects on skin tone and turgor, promoting hydration and thus aesthetic appearance.
The results of various clinical trials published in the literature, on various hyaluronic acid gels are generally in agreement: indeed, both from the viewpoint of the physician and the patient, very satisfactory improvements are observed with skin defects, and the degree of correction has been evaluated as between 60 and 90%, 6-9 months after the first injection (Duranti F. et al. 1998; Olenius M. 1998; Carruthers J. et al., 2005; S. di Bosniak et al., 2004; Narins R. S. et al. 2003; Lindqvist C et al., 2005; Carruthers J. & Carruthers A., 2003).
As already mentioned previously, among the fundamental components of the extracellular matrix of connective tissue and hence skin, we find the glucosaminoglycans (GAGs) and hyaluronic acid, and the characteristics, properties and functions of the latter have already been exhaustively described and specified.
In both cases, from the structural viewpoint, these are unbranched glucosidic polymers, wherein the repetitive unit is constituted by disaccharides, the monomers of which are represented by uronic acids such as glucuronic, galacturonic or iduronic acid and aminosugars such as N-acetylglucosamine or N-acetyl galactosamine, variously substituted.
From the above, it is simple to deduce that, besides HA, there are other substances that may be extremely important in preserving and/or improving skin functionality and aesthetic appearance. One of these is NAG.
There are studies available in the literature and tests, described below in the experimental section of the present patent application, showing how NAG exerts an indisputable positive action on skin characteristics and functionality, so as to justify and recommend its advantageous use in dermo-cosmetology and aesthetic medicine. Thus, for example:
From the description provided in the introduction, it is clearly obvious that the use of both exogenous HA and NAG is certainly effective and to be recommended in preparations for topical (dermo-cosmetology) and intradermal (aesthetic medicine) use.
The present invention is based on recognition of the fact that NAG activity is potentiated thanks to the association between NAG and an alkaline metal sulphate within a defined weight ratio range. Thus, a synergic composition, as defined in the following claims, constitutes the subject of the invention.
According to the invention, a molecular composition between NAG and an alkaline metal sulphate (hereinafter anhydrous sodium sulphate (ASS) will be used as ponderal reference) has been realised and studied, wherein the equivalent mass ratio between NAG and ASS may vary between 1:0.5 and 1:3, then practically using, for reasons that will be clarified in the experimental section, the most advantageous ratio, i.e. 1:1 (corresponding in ponderal terms to 75.7% NAG and 24.3% ASS). With regard to this subject, it should be highlighted that, in order to avoid confusion, hereinafter, the molecular combination corresponding to the experimentally most advantageous ratio between equivalent masses, i.e. 1:1 will be known as Condramina (CA) while all other combinations in the range 1:0.5-1:3 (obviously excluding 1:1), will be identified by the abbreviation COMBI. After a preliminary experimental stage, revealing the advantageous use of CA with respect to all the other COMBI preparations (in any case convenient with respect to the use of NAG at corresponding doses), the activities of CA in stimulating the expression of HA, collagen, elastin and other proteins, in “in vitro” cultures of fibroblasts and keratinocytes, have been tested and compared with those of NAG and sodium sulphate, taken individually and in doses/concentrations corresponding to those present in CA, used in the same tests.
The concentrations of HA described and claimed in the present patent application do not exceed 4% and are preferably comprised in the range 1-3%.
COMBI is composed of NAG and ASS in equivalent mass ratios varying between 1:0.5 and 1:3 (excluding the ratio of 1:1 already identified as Condramina (CA)), corresponding to ponderal ratios oscillating between 86.17% and 50.93% for NAG and between 13.83% and 49.07% for ASS:
CA is composed of NAG and ASS in an equivalent mass ratio equal to 1:1, corresponding in ponderal terms to 75.7% CA and 24.3% ASS
Both COMBI and CA are constituted by:
a. NAG:
The concentrations/doses of CA used within the scope of the invention are preferably comprised of between 0.05% and 2.5% by weight, and more preferably between 0.1 and 0.5% with regard to the topical and intradermal forms while, if used for oral administration, CA may be taken in daily doses, expressed in terms of glucosamine base, comprised of between 100 and 1000 and preferably 250-750 mg, in one or more administrations, depending on the dose and pharmaceutical form used.
The synergistic effect achieved by the composition according to the invention has been verified through a series of “in vitro” tests, evaluating and comparing the experimental results in relation to Condramina (CA) with those of its components, i.e. N-acetylglucosamine (NAG) and anhydrous sodium sulphate (ASS) considered individually, at concentrations consistent with the ratio between their equivalent masses in CA, shown to be the most convenient i.e. 1:1. Said ratio has been selected on the basis of the results of a preliminary test where the evaluation has been focussed on the experimental effect of the variation of the reciprocal ratio of NAG and ASS in COMBI.
The tests selected have been:
The test has been conducted in two stages, i.e.:
Human fibroblasts, Detroit 551 ATCC CCL III from LGC Promochem (Milan, Italy) have been used.
The substances tested for their effect on the expression of HA in human fibroblast cultures have been:
Human fibroblasts have been grown in suitable growth medium (Eagle's minimal essential medium) supplemented with 10% foetal calf serum (FCS), 1 mM sodium pyruvate, 2 mM glutamine, non-essential aminoacids and 50 μg/ml glutamycin. Confluent cells have been plated in 24 well plates, 5×104 cells/well, using the same medium. At confluence, the cells have been pre-exposed to medium containing 5% serum, prior to the addition of the test substances at the desired concentrations. After 48 hours, the supernatant has been removed and used for the determination of the parameters of interest. The test has been conducted in duplicate and untreated cell cultures have been used as controls.
HA has been assayed (dosed) by means of an immuno-enzymatic test using a commercially available kit (EIA, Corgenix). De novo HA synthesis has been evaluated in the culture medium following treatment with the test substances, according to the protocol provided with the test, and against the calibration curve obtained using the HA standard contained in the kit.
The percentage difference increase or decrease of the effects exerted by CA and NAG, at corresponding concentrations, have then been calculated, with evaluation of their potential significance by means of the Student's “t” test.
2001)
The scope of the test has been the evaluation and the comparison of the potential stimulation exerted by the test substances on the expression of collagen and elastin in “in vitro” cultures of skin-derived cells, such as fibroblasts. The test in question, even though conducted “in vitro”, can be considered to be predictive of the effects of use of the same substances “in vivo”.
Human fibroblasts, Detroit 551 ATCC CCL III from LGC Promochem (Milan, Italy) have been used.
The substances and concentrations tested have been the same as those already described for stage B of the test on the stimulation of HA expression, i.e.:
Cells have been plated out in 96 well plates, 2500 cells/well for 24 hours in cell growth medium (Dulbecco's Minimum Essential Medium, DMEM)+10% foetal calf serum (FCS). Fresh culture medium, enriched with just 5% FCS and containing the substances to be tested, so as to reach the final concentrations desired, has then been added. The samples have been dissolved directly in the culture medium. Each sample has been tested in duplicate and the experiments have been repeated twice. The parameters of interest have been determined after 24 hours on separate plates. Untreated cell cultures have been used as controls.
A commercially available kit (Sircol™, biodye science) which uses the capacity of the stain Sirius Red to interact with the basic side chains of the aminoacids present in collagen itself, has been used for collagen assays. De novo collagen synthesis has been evaluated in the culture medium following treatment with the test substances, following the protocol provided with the kit, and by using the calibration curve obtained employing the collagen standard contained in turn in the kit.
Elastin has been assayed using a commercially available test (Fastin™, biodye science). The assay is based on the interaction of 5,10,15,20-tetraphenyl-21,23-porphyrin with elastin molecules.
De novo elastin synthesis has been evaluated in the culture medium following treatment with the test substances, following the protocol provided with the test, and by using the calibration curve obtained employing the elastin standard contained in the kit itself.
Evaluation of the effects of the substances tested, at the various concentrations, on fibroblast cultures, has been expressed as the absolute and percent increase or decrease of collagen and elastin expression, with respect to the corresponding control culture, after 24 hours of incubation.
The percentage difference increase or decrease of the effects exerted by CA and NAG, at corresponding concentrations, have then been calculated, with consequent evaluation of their potential statistical significance by means of the test Student “t” test.
Fibroblasts and keratinocytes, present in the dermis and epidermis, besides being involved in the synthesis of collagen, elastin and HA, are also involved in the expression of various protein species including, for example, keratin by keratinocytes and the so-called core e link-proteins, onto which are attached various types of GAGs to form proteoglycans, which are in turn, fundamental components of extracellular matrix.
The level of viability and the efficiency of such cells, in the presence or absence of agents whose beneficial action towards skin it is desired to verify, may be evaluated and deduced from their protein synthetic capacity.
The following have been used:
The substances and concentrations tested are those reported below (on both fibroblasts and keratinocytes):
Based on the previously mentioned information relating to indicators of efficiency of cells present in the skin, the scope of the test has been the evaluation and comparison of the potential stimulation, exercised by the test substances, on protein expression in “in vitro” fibroblast and keratinocyte cultures.
The test in question, even though conducted “in vitro”, can be considered to be predictive of the effects of use of the same substances “in vivo”.
The method is identical to that already described for collagen and elastin with the difference that, following the addition of the test substances into the culture medium, the medium has been substituted daily for three days. Each sample has been tested in duplicate and the experiments have been repeated twice. The parameter of interest, i.e. protein synthesis, has been evaluated at 24, 48 and 72 hours on separate plates. Untreated cell cultures have been used as controls.
Protein has been assayed using the Lowry method [Lowry et al. 1951] consisting of a Biuret reduction reaction envisaging the use of Folin-Ciocalteau reagent as chromophore, with a yellow to blue colour change and spectrophotometric measurement at 750 nm [Creighton et al. 1984; Sengupta et al. 1993].
The protein content of the cultures in question has been obtained from comparison of their optical densities with a titration curve made using albumin as a protein standard.
Evaluation of the effect of the substances tested, at the various concentrations and times, on cultures of both fibroblasts and keratinocytes has been expressed in both absolute terms (expressed protein production in mg/ml) and as percentage increase or decrease with respect to control cultures.
The percentage difference increase or decrease of the effects exerted by CA and NAG, over various days and at the corresponding concentrations, have then been calculated, with evaluation of their potential statistical significance by means of the test Student “t” test.
The particular characteristics of substances to be used for topical or intradermal use in cosmetics must be absolutely free from any cytotoxic effects within the dose/concentration range for their intended practical application.
There are appropriate “in vitro” tests, conducted on cells derived from skin tissue, such as fibroblasts and keratinocytes, for predicting the potential cytotoxicity of test substances “in vivo”.
For this purpose the cell viability test using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) [Mossman 1993] a colourimetric reagent, by means of which it is possible to distinguish between living, damaged or dead cells, being thus predictive of the safety of use of test substances, even “in vivo”, has been selected.
The following have been used:
Since, in the composition forming the subject of the present invention, NAG and ASS are never claimed for individual use, but always in association in the composition of CA, the only substance tested for its potential cytotoxic effect has been CA, at such concentrations as to be predictive and referable to those used in “in vitro” activity testing on the previously described fibroblast and keratinocyte cultures.
In the study in question, CA has been previously dissolved and brought into contact with the selected cell cultures in such a manner as to directly reach the desired concentrations, i.e.:
0.026, 0.053, 0.106, 0.211, 0.409, 0.818, 1.65 and 3.30 mg/ml.
Analogous samples of untreated human fibroblasts and/or keratinocytes have been used as negative controls.
Analogous samples of human fibroblasts or keratinocytes have been treated with a surfactant of known activity (SDS), dissolved in culture medium at concentrations comprised of between 0.05 and 1.6×10−3 mg/ml, and used as a positive control.
Exposure has been for a period of 24 hours, on completion of which, the cytotoxicity test has been conducted.
As already mentioned, the key reagent is MTT, a yellow-coloured substance in aqueous solution which, when acted-on by the mitochondrial dehydrogenases present in viable cells, is transformed into purple crystals, insoluble in water, but soluble in acidified isopropanol. The absorbance of the resulting purple solution at 540 mm is used as an indicator of the level of cytotoxicity of the substances under test.
In operational terms, the key reagent is prepared by adding 15 mg of MTT to 30 ml of culture medium. Aside, after 24 hours in contact with the test substance and/or SDS, the fibroblasts or keratinocytes are washed with 400 μl of wash solution (Dulbecco's Phosphate Buffered Saline, DPBS) and, following removal of the solution, 200 μl of MTT medium added, and the cell samples incubated for 4 hours at 37° C. On completion of the incubation period, the MTT medium is removed and 400 μl of MTT solubilising solution added (10% Triton X-100+0.1 N HCl in anhydrous isopropanol). The plates are shaken for 20-30 minutes until a homogenous solution is formed, the absorbance of which is then read at 540 m with a background reading at 670 nm.
Results are expressed as:
The cytotoxicity data, obtained using the MTT test, is plotted on a graph against the concentration of the product under test, thus giving a dose-response curve, allowing the determination of:
From the results reported in Table 3, Stage A, it is obvious that there is clear synergism between NAG and ASS depending on the ratios, in terms of equivalent mass, varying between 1:0.5 and 1:3 with the most favourable verifiable ratio being 1:1. For combinations outwith said favourable range, no synergism is detectable, since the effect of the combination between NAG and ASS under such conditions is even less than that of NAG alone and at concentrations corresponding to that present in the combination itself.
Indeed, it may be observed how for a NAG/ASS ratio equal to 1:0.4 (the most favourable to NAG), the increase in HA expression is approx. 65%, markedly inferior than that for NAG at the same concentration, which is certainly greater than 75%. Analogously, for a NAG/ASS ratio equal to 1:3.5 (the most favourable to ASS), the increase is approx. 50% compared to that of NAG alone, which approaches 60% at the same concentration.
From the results reported in tables 1 to 3, Stage B, it is possible to draw the following conclusions:
From the results reported in tables 5-7 it is possible to draw the following conclusions:
From the results reported in tables 8-10 it is possible to draw the following conclusions:
On the other hand, both CA and NAG, at the concentrations tested and consistent with one another, exert a very marked stimulatory effect that, in both cases, is already apparent at the lowest concentration tested i.e. 0.5 mg/ml for NAG and 0.66 mg/ml for CA (corresponding to 0.5 mg/ml NAG) increasing in a dose-dependent manner until exceeding 300% with respect to the baseline control, at the maximum concentration i.e. 2.5 mg/ml NAG and 2.64 mg/ml CA (corresponding to 2.5 mg/ml NAG).
From the results reported in table 13 it is possible to draw the following conclusions:
Particularly, by examining and comparing the actions exerted by the two substances at 48 hours, i.e. at the peak of their stimulatory effect (said comparison at 24 and 72 hours has little significance since it is either temporally premature or late) it is clear that CA exerts a markedly superior stimulatory action on protein expression in keratinocytes than that of NAG at corresponding doses. This experimental results is further confirmed by the Student “t” value, applied to the differences in percentage stimulation of the two test substances, which is highly significant.
Hence, once more, the unexpected and unforeseen synergic effect between ASS and NAG is proven, making the functional and formulative use of CA certainly preferable and advantageous with respect to NAG at equivalent concentrations and/or dosages.
From the results reported in table 14 it is possible to draw the following conclusions:
The appearance of the stimulatory effect is already evident at 0.5 mg/ml for NAG and at 0.66 mg/ml for CA, increasing in a dose-dependent manner (significant correlation coefficient for the concentration/effect regression in both cases, i.e. r=0.844 for NAG and 0.845 for CA) up to the maximum concentration tested, i.e. 2 mg/ml for NAG and 2.64 mg/ml for CA.
As already highlighted previously, the stimulation exerted by both test substances is very marked, reaching and exceeding, at the maximum concentrations tested, an increase of 50% with respect to the protein expression of control cultures, and thus confirming the highly positive effect exerted by both active substances on the specific functions of cells of cutaneous origin, such as fibroblasts and keratinocytes.
As already explained in the descriptive section, inhibition of cellular viability has been calculated on a series of fibroblast cultures, in the presence of a set of concentrations established for CA, and by applying the formula (I) wherein “OD540 treated cells” represents the absorbance at 540 nm of the cultures containing CA and “OD540 untreated cells” that of the negative control (blank). Test efficiency is assessed on a culture containing a highly cytotoxic surfactant, i.e. sodium dodecylsulphate (SDS), at a concentration (0.05 mg/ml) at which the absorbance at 540 nm should be practically zero being the bacterial growth completely inhibited.:
The results obtained are reported in the following table:
From the tabulated data, the following conclusions may be drawn:
In the case of CA, since at the maximum concentration tested, i.e. 3.30 mg/ml, the percentage inhibition of cell viability does not even reach 20% (18.44%), it is obvious that the IC50 is much less than 1.5 mg/ml and therefore CA, according to data deduced from the “in vitro” predictive model, it may be considered devoid of any cytotoxic potential towards human skin-derived fibroblasts, and as such freely usable, both for topical use and as an intradermal filler.
In the case of keratinocytes, for which the same MTT test and the same evaluation criteria, deducible from the IC50 value, have been used, the results obtained are reported in the following table:
From the tabulated data, the following conclusions may be drawn:
The experimental results summarised above highlight at least two fundamental considerations i.e., firstly, the surprising effect associated with the combination between NAG and ASS (as both CA and as COMBI), unpredictably and unexpectedly advantageous with respect to NAG at consistent doses but without the synergic support of ASS (ASS alone has no effect), and secondly, the synergic effect between the components which reach their maximum, in the case of CA, at a ratio, expressed in terms of equivalent mass, equal to 1:1, declining progressively at values either side of this central value.
If to the above is added the complete absence of any potential cytotoxic effects of the composition according to the invention (the lack of toxicity of its components, if administered orally, being well known), it may be concluded that its potential use in association with other active ingredients, such as for example HA, preferably at doses/concentrations and according to the formulations described and claimed in the present patent application, results advantageous and safe use, both for oral administration, for example in dietary supplement formulations, and for topical application or as an intradermal filler in restoring skin tone and vigour.
(1)NAG to ASS ratio outwith the range of COMBI
(2)NAG to ASS ratio within the range of COMBI
(3)NAG to ASS ratio corresponding to CA
(***)SS = Statistically significant
(**)NS = Not statistically significant
(***)SS = Statistically significant
(***)SS = Statistically significant
The formulations reported below, along with the description of the operating procedures used in examples 1 and 2, illustrate possible practical applications of the present invention and, since they are purely by way of example, should not be considered limiting of the invention itself in any way.
Particular reference is made to the excipients, which may be used alternatively to those explicitly mentioned in the present invention, in accordance with formulative-technological requirements, and which, in any case, may be selected from a vast range of products available on the market and well known to those skilled in the pharmaceutical sector, and hence of no inventive originality.
With regard to the dosage of active ingredients, the samples described report purely indicative quantities, any variation to which does not result in substantial modification to the methods of preparation illustrated.
More precisely, HA, expressed as sodium salt, may be advantageously used at concentrations no greater than 4% (preferably 1-3%), while CA may vary between 0.05 and 2.5% (preferably 0.1-0.5%) in accordance with the concentrations used in the “in vitro” tests, described in the experimental section and with the amount contained in the claims of the present patent application.
The formulation, reported in Table 1, concerns active ingredients and excipients (with description of the corresponding technological function) that may be used in the preparation of a solution for topical application, to be automatically batched into disposable containers of set volume.
The material used for the containers, for example polyethylene, must be compatible with the components of the formulation and with current standards for materials for use in the cosmetics field or for a medical device.
A preparation example of the formulation in question to be batched into monodose polyethylene containers, is hereinafter described:
(1)Molecular weight comprised of between 0.5 and 3 × 106 Da
(2)The quantity of sodium hyaluronate weighed out may be duly adjusted according to its strength in order to comply with the stated content in the final solution.
(3)Composed of 75.7% NAG and 24.3% anhydrous sodium sulphate i.e. according to the weight ratio corresponding to the respective equivalent masses.
The formulation, reported in Table 2, concerns active ingredients and excipients (with description of the corresponding technological function) that may be used in the preparation of a moisturising lipogel for topical application, to be batched, for example, into multidose containers. The material used for the container, for example polyethene, must be compatible with the components of the formulation and with current standards for materials for use in dermo-cosmetology or for a medical device.
A preparation example of the formulation in question to be batched into multidose containers, is reported below by way of example:
(1)Composed of 75.7% NAG and 24.3% anhydrous sodium sulphate i.e. according to the weight ratio corresponding to the respective equivalent masses
(2)A special composition of HA in biospheres (see Table 3) which, following application onto the surface of the skin on the face, penetrates into fine wrinkles and captures evaporation water, thus swelling with consequent natural reactivation of the skin surface. The resulting smoothing activity is also due to the external filling of the wrinkles themselves by the biospheres remaining on the surface of the skin
(3)The use of biospheres is an entirely optional improvement. Alternatively, they can be replaced with such quantities of HA as to obtain the same aesthetic results. HA/ethyl-hexyl-palmitate is normally commercially available
(4)A component consisting of special silicone elastomers, in the shape of small spherical particles, capable of uniformly reflecting incident light. The particles stick inside the furrow of the wrinkles, with a consequent surface smoothing effect and an obvious aesthetic impact.
(*)Low molecular weight
(**)High molecular weight
The series of operations described in example 3 must be considered purely as one of the explanatory examples of the present invention and since the procedures described have no inventive originality and do not represent any technological novelty for those skilled in the art, they must not be considered limiting of the invention itself in any way.
With regard to the concentrations and physico-chemical characteristics of the two active ingredients, the information provided for examples 1 and 2 remains valid.
The formulation reported in table 4 concerns active ingredients and excipients (with descriptions of the corresponding technological functions) that may be used in the preparation of viscoelastic solutions, to be used as a medical device for intradermal use in dermo-cosmetology and aesthetic medicine.
Similarly, the packing materials used must be compatible with the formulation components and with the current regulations governing use in the production of a medical device.
A preparation example of the class of formulation in question, to be batched into monodose syringes of the desired volume, is reported below:
Check and if necessary adjust the pH to 7.2 with 1 N HCl or 1 N NaOH;
(1)Molecular weight comprised of between 0.5 and 3 × 106 Da
(2)The quantity of sodium hyaluronate weighed out may be duly adjusted according to its strength in order to comply with the stated content in the final solution
(3)Composed of 75.7% NAG and 24.3% anhydrous sodium sulphate i.e. according to the weight ratio corresponding to the respective equivalent masses.
Examples 4 and 5 describe two procedures in which CA and crosslinked HA are incorporated into a single formulation, giving hydrogels to be used for intradermal administration.
In both cases, there is a preliminary stage, i.e. the crosslinking of HA, which is not covered by the claims contained in the present invention, but which is described all the same, at least in summary, in order to make the procedures reported in the examples in question comprehensible and homogeneous.
The crosslinking process described has no technological novelty for the sector, and so it is emphasised that no claimable inventive originality may be attributed to it, unlike the final hydrogels, containing crosslinked HA together with CA, never previously described and claimed due to the absolute novelty represented by the formulations including them.
The above-mentioned crosslinking process essentially consists of the formation of molecular bridges connecting the individual HA units to one another by means of the formation of covalent bonds with the bifunctional molecules of the crosslinking agent. This way, three-dimensional structures of variable consistency are formed, which, in water or in physiological liquids, have the capacity to reswell to a state of equilibrium directly in proportion to the degree of crosslinking.
On HA, there are two reaction centres, suitable for the formation of bridges by means of interaction with bifunctional agents, i.e.:
There is a vast range of well known crosslinking agents, widely used and easily available on the market, and from among these, we may cite by way of example:
Among the above-mentioned crosslinking agents, BDDE is preferable due to its very low toxicity and, for this reason, it is used in the formulations described and claimed in the present patent application, and consequently, in the detail of examples 4, 5.
For each crosslinking agent, there are precise practical modes of use and, in the case of BDDE, the process is achieved through the formation of ether bonds with the hydroxyl groups of NAG under the working conditions specified herein:
With regard to the dosage of active ingredients, the samples described report purely indicative quantities, and any variation to the same does not result in modification to the methods of preparation illustrated. Furthermore, such quantities are in keeping with the required conditions for the use of BDDE as a crosslinking agent, and are within the ranges already specified in examples 1, 2 and 3. For further clarity, the formulation relating to examples 4 and 5 is summarised quantitatively in table 5.
The process is outlined in detail by means of the steps and stages described below:
a. Preparation of the 2% crosslinked HA Hydrogel
Over the course of the above-described operations, check the pH of the external isotonic solution and the osmolarity of the final hydrogel repeatedly, which must correspond to that related to the predefined HA concentration (osmolarity comprised of between 260 and 360 mOsm/l and pH comprised of between 6.8 and 7.6)
b. Preparation of the Isotonic, pH 7.2 Buffered Solution, Containing the Predetermined Concentration of CA (0.1%)
The process is outlined in detail by means of the steps and staged described below:
The final packaging is subsequently subjected to a sterilisation process, compatible with the formulation and the materials with which it is composed.
(1)in sodium salt form. Molecular weight comprised of between 0.5 and 3 × 106 Da
(2)the quantity of sodium hyaluronate weighed out may be duly adjusted according to its strength in order to comply with the stated content in the final solution
(3)composed of 75.7% NAG and 24.3% anhydrous sodium sulphate i.e. according to the weight ratio corersponding to the respective equivalent masses.
(*)To be used only if necessary
The formulations reported hereinafter illustrate potential practical applications of the present invention, and as such, must not be taken to be limiting of the invention itself in any way.
Particular reference is made to the excipients of the various forms under consideration, which may be used alternatively to those explicitly mentioned in the examples illustrated below, depending on the formulative-technological requirements, and which, in any case, may be selected from a vast range of products available on the market and well known to those skilled in the pharmaceutical sector, and hence of no inventive originality.
Also in the case of the oral forms, the CA dosage given in the examples is purely indicative and is in any case within the dosage range claimed in the present inventive description, i.e. variable between 100-1000 and preferably 250-750 mg per day, expressed in terms of glucosamine base.
The same is also true for the NAG to ASS ratio within CA, which, as previously specified, can vary freely in terms of equivalent mass between 1:0.5 and 1:3 and which, in the examples described, has been maintained constant and equal to 1:1 being the most advantageous according to the findings of the experimental section.
It should also be specified that, any variations in the dosage of CA and the content thereof in relation to NAG and ASS do not imply any substantial modifications to the preparation methods illustrated.
Besides the active ingredient, the formulation reported in Table 7 comprises excipients (with a description of the corresponding technological function) that may be used in the preparation of tablets to be used for the oral administration of the subject of the present invention, alone or in association with other active ingredients.
The vehicularisation technique of the selected dose of CA, alone or in association with other active ingredients, in a tablet, requires only operations that are technologically well known and entirely normal for any operator in the art, i.e.:
(1)the quantity of CA is formulated and calculated so that the ratio between NAG and ASS, in terms of equivalent mass, is 1:1 (75.7% NAG and 24.3% ASS by weight) corresponding to a content, expressed in glucosamine base, equal to 500 mg (MW of NAG = 221.2; MW of glucosamine base = 179.2: thus, in ponderal terms, 221.2 mg of NAG corresponds to 179.17 mg of glucosamine base)
(2)used in the preparation of the CA granulate
(3)the absolute and relative quantities of said excipients depend on the size and shape of the compression die, the type of tabletting machine and the system for loading the powders into the compression chamber installed inside
(4)water is used in the preparation of granulate A and its amount depends on the components of the granulate as well as type and size of the granulator used. It is completely eliminated during drying
Besides the active ingredient, the formulation reported in Table 8 comprises excipients (with a description of the corresponding technological function) that may be used in the preparation of hard gelatine capsules to be used for the oral administration of the subject of the present invention, alone or optionally in association with other active ingredients.
The vehicularisation technique of the selected dose of CA, alone or in association with other active ingredients, in a hard gelatine capsule, requires only operations that are technologically well known and entirely normal for any operator skilled in the art, i.e.:
(1)see the remarks in note (1) of table 7 for calculating the dosage of CA and the mass ratios between NAG and ASS.
(2)the absolute and relative quantities of the excipients depend on the size of the capsules used as administration vehicle and the dosing type/system installed in the filler used for batching the formulation into hard gelatine capsules.
Besides the active ingredient, the formulation reported in Table 9 comprises excipients (with a description of the corresponding technological function) that may be used in the use of the subject of the present invention, alone or optionally in association with other active ingredients, in the formulation of a powder for the preparation of extemporaneous solutions/suspensions to be taken orally.
For this purpose, the formulation in question may be suitably vehicularised in a thermosealed sachet constituted by an outer layer of paper, an aluminium interface and an inner layer f polyethylene, using preparation operations well known and useable by any technical staff operating in the specific field, i.e.:
(1)see the remarks in note (1) of table 7 for calculating the dosage of CA and the mass ratios between NAG and ASS.
(2)the absolute and relative quantities of said excipients depend on the type of sachet filler used and the sachet sizes.
(3)flavourings and sweeteners may be added freely, depending on the organoleptic preferences.
| Number | Date | Country | Kind |
|---|---|---|---|
| TO2007A000210 | Mar 2007 | IT | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP08/53286 | 3/19/2008 | WO | 00 | 9/16/2009 |
